Anaptysbio (ANAB) Non-Current Deffered Revenue (2016 - 2018)
Anaptysbio (ANAB) posted Non-Current Deffered Revenue of $171000.0 for Q4 2018, up 5.56% on a QoQ basis from $162000.0 in Q3 2018, and up 22.14% year-over-year from $140000.0 in Q4 2017.
Anaptysbio (ANAB) Non-Current Deffered Revenue (2016 - 2018) Analysis & Trends
Anaptysbio's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $171000.0 for Q4 2018.
- Quarterly Non-Current Deffered Revenue rose 22.14% year-over-year to $171000.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $171000.0 (up 22.14% YoY) and the FY2018 annual result came in at $171000.0, up 22.14% from the prior year.
- Non-Current Deffered Revenue was $171000.0 for Q4 2018 at Anaptysbio, up from $162000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $171000.0 in Q4 2018 and bottomed at $128000.0 in Q2 2018.
- A 3-year average of $151555.6 and a median of $154000.0 in 2016 frame the typical range for Non-Current Deffered Revenue.
- Peak annual rise in Non-Current Deffered Revenue reached 22.14% in 2018, while the deepest fall reached 23.81% in 2018.
- Anaptysbio's Non-Current Deffered Revenue stood at $154000.0 in 2016, then fell by 9.09% to $140000.0 in 2017, then climbed by 22.14% to $171000.0 in 2018.
- Business Quant data shows ANAB's Non-Current Deffered Revenue at $171000.0 in Q4 2018, $162000.0 in Q3 2018, and $128000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Anaptysbio | 1.58 Bn | 1.29 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 171,000.00 |
| Sep 30, 2018 | 162,000.00 |
| Jun 30, 2018 | 128,000.00 |
| Mar 31, 2018 | 133,000.00 |
| Dec 31, 2017 | 140,000.00 |
| Sep 30, 2017 | 147,000.00 |
| Jun 30, 2017 | 168,000.00 |
| Mar 31, 2017 | 161,000.00 |
| Dec 31, 2016 | 154,000.00 |